Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Targeting p53 pathways: mechanisms, structures and advances in therapy
Haolan Wang, Ming Guo, Hudie Wei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 389
Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 98
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 47
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 46
Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
Yu-Ling Tseng, Po-Chao Lu, Chi-Chang Lee, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 32
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8822-8843
Closed Access | Times Cited: 29
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 24
Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer
Yun Ju Lee, Woo Ryung Kim, Eun Gyung Park, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4548-4548
Open Access | Times Cited: 12
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 12
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 11
Repurposing AS1411 for constructing ANM-PROTACs
Xuekun Fu, Jin Li, Xinxin Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1290-1304.e7
Closed Access | Times Cited: 10
Targeting androgen receptor degradation with PROTACs from bench to bedside
Xiaojuan Jia, Xin Han
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114112-114112
Open Access | Times Cited: 36
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 22
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
Chong Feng, Lening Zhang, Xin Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
The role of the MDM2/p53 axis in antitumor immune responses
Tilman Brummer, Robert Zeiser
Blood (2023) Vol. 143, Iss. 26, pp. 2701-2709
Open Access | Times Cited: 17
Tubulin degradation: Principles, agents, and applications
Yifan Zhang, Jiao Huang, Weixin Zhang, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106684-106684
Closed Access | Times Cited: 15
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
Ali Alaseem
Saudi Pharmaceutical Journal (2023) Vol. 31, Iss. 10, pp. 101790-101790
Open Access | Times Cited: 14
Modulation of macrophage polarity with carboxymethyl chitin gated hollow mesoporous silica nanoparticles for elevating anti-tumor chemotherapy
Xin Ding, Xiyu Liu, Tao Qiu, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129761-129761
Closed Access | Times Cited: 5
P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds
Gazmend Temaj, Silvia Chichiarelli, Pelin Telkoparan‐Akillilar, et al.
Biochemical Pharmacology (2024) Vol. 226, pp. 116332-116332
Closed Access | Times Cited: 5
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107868-107868
Open Access | Times Cited: 5
Targeted regulated cell death with small molecule compounds in colorectal cancer: Current perspectives of targeted therapy and molecular mechanisms
Ru Li, Yongya Wu, Yan Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116040-116040
Closed Access | Times Cited: 11
Ubiquitin recruiting chimera: more than just a PROTAC
Tatyana A. Grigoreva, Daria Novikova, Gerry Melino, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 4
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Page 1 - Next Page

Scroll to top